Harbour BioMed partners Otsuka on new T-cell therapy
Pharmaceutical Technology
JUNE 23, 2025
Otsuka Pharmaceutical president and representative director Makoto Inoue noted: “HBM7020 is expected to demonstrate efficacy in a broad range of autoimmune diseases in which B cells play a major role in disease pathogenesis, and we hope to contribute further to the field of specialised autoimmune diseases and thereby benefit patients.”
Let's personalize your content